近些年来,TP53 突变与血液系统疾病的相关性研究逐渐成为热点,不论在淋巴瘤还是在白血病中,伴随 TP53 突变均提示高风险或预后不良,有效且高质量的移植对患者至关重要[3]。 131I-apamistamab 引导的 HCT 显著改善了伴 TP53 突变的 R/R ...
魏辉教授 在AML中,FLT3内部串联重复(ITD)突变、TP53突变、骨髓增生异常相关基因突变如RUNX1突变等与预后不良相关,伴有这些突变的患者通常对化疗不敏感或耐药,移植疗效相对较差。其中,FLT3突变的发生率较高,主要有两种类型,即ITD突变和酪氨酸...
TP53 mutations are adverse-risk genetic aberrations in acute myeloid leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53MUT) AML remains unclear. We aimed to evaluate the prognostic implications of different frontline treatment strategies and transplantatio...
基因数据现在被使用于患者的疾病分类、风险分层和临床治疗。Two new provisional entities, AML with mutated RUNX1 and AML with BCR-ABL1, have been included in the current update of the WHO classification of myeloid neoplasms and AML, and mutations in three genes—RUNX1, ASXL1, and TP53—have bee...
Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
These findings suggest that incorporating MRD testing into treatment plans could help personalize therapy, potentially improving long-term survival for patients with TP53-mutant MDS and AML. David Sallman, MD, Moffitt Cancer Center, discussed the trial's im...
131 I‑Apamistamab-led Allogeneic hematopoietic cell transplant significantly improves OS in patients with TP53 mutated R/R AML. Blood. 2023;142(Supplement 1):469. Article Google Scholar Yilmaz M, Muftuoglu M, DiNardo CD, et al. Phase I/II study of Quizartinib, Venetoclax, and ...
We’ve seen in MDS that magrolimab and azacitidine seems to lead to similar CR rates for patients with TP53-mutated disease and those who don’t have TP53-mutated disease. There is some excitement that this may be a benefit to those very high-risk patients. The other promising therapy is...
(excluding hyperdiploid), monosomal karyotype Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 Mutated TP53 with VAF ≥10% aAdapted from (Cornelissen et al. 2012b), Table 4 bAllo-HCT using HLA-identical sibling or 10/10 MUD donors cAdapted from (...
儿童AML诊治新进展 儿童AML诊治新进展 AML的分类与时俱进 1970 •基于骨髓和外周血形态检查建立诊断 1985 •根据细胞化 学和免疫组 化特征，在 1976 1976年FAB 分型标准上 •基于标准化的增加M0与 染色技术，FAB形态诊断 M7两个亚型 标准形成，分 为M1～M6 1998 WHO首次整合了细胞遗传学，临床表现以及形态...